Medicxi Ventures Closed a New 400 Euro Fund to Power the Next Wave of Biopharma Entrepreneurs & Drug Hunters

Jul 20, 2019 | European Financing, Private Equity, Venture Capital

Female medicine doctor shake hand as hello

Medicxi Introduces the 400 Medicxi III fund, closed in just six weeks, and brings the total funds raised in the last three years to over $1b. They will invest across the full healthcare continuum, from discovery to late-stage clinical assets, empowering ambitious scientific entrepreneurs and drug hunters. Novartis and Johnson & Johnson Innovation—JJDC, Inc. are returning cornerstone investors, with new investors including established hospital foundations and medical institutions.

Leading European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new €400 million fund. This brings the total amount raised by Medicxi in the last three years to over $1 billion.

From this single fund, Medicxi will invest in early and late-stage biopharma companies across the full healthcare continuum from discovery to late-stage clinical assets. Cornerstone’s strategic investors in Medicxi III are Novartis and Johnson & Johnson Innovation – JJDC, Inc. (JJDC), both of whom have backed Medicxi in earlier funds. The fund also includes all of the institutional limited partners that previously invested in Medicxi’s funds, as well as several new investors, including established hospital foundations and medical institutions. 

Medicxi III will be supported by the Medicxi Scientific Advisory Board, which benefits from the scientific and commercial expertise of senior executives from Novartis, the Janssen Pharmaceutical Companies of Johnson & Johnson, GlaxoSmithKline and Verily (an Alphabet company). 

The new fund will continue to focus on Medicxi’s pioneering ‘asset-centric’ investment model as well as investing in fully integrated private companies with an underlying platform and/or a pipeline of assets that Medicxi believes can deliver licensed pharmaceutical products to satisfy unmet medical needs.

The size of the fund and the speed with which it was closed reflects the continued maturity of the life sciences sector across Europe, with investors now prioritizing their attention and support for emerging biopharma companies and their efforts to translate breakthrough science into pipelines of new drugs.

Francesco De Rubertis, co-founder and Partner at Medicxi, said: “Medicxi III is one of the largest biotech funds in Europe and consolidates Medicxi’s position as a key operating platform for scientific entrepreneurs and drug hunters. We are grateful to our LPs who made it possible to get the fund closed within only a few weeks.”

Enquiries:

Medicxi

Ursula Lucas +41 22 707 8639

ursula@medicxi.com 

Instinctif Partners (International Media)

Sue Charles / Alex Bannister / Phil Marriage +44 20 7866 7863

medicxi@instinctif.com 

VEITHing Spirit (Swiss media)

Marcus Veith +41 22 78 65 603 Office / +41 79 20 75 111 Cellphone

marcus@vspirit.ch

0 Comments

Pin It on Pinterest